Abbvie Inc
ABBV
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2026
July 31, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
29.2% downsideOvervalued by 29.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $443.24 Billion |
|---|---|
| Enterprise Value | $506.71 Billion |
| Dividend Yield | $6.83 (2.72%) |
| Earnings per Share | $2.37 |
| Beta | 0.28 |
| Outstanding Shares | 1,773,864,000 |
Return
| Return on Equity | 13.23% |
|---|---|
| Return on Assets | 2.67% |
| Return on Invested Capital | 12.29% |
Valuation & Multiples
| P/E Ratio | 123.01 |
|---|---|
| PEG | -269.49 |
| Price to Sales | 7.17 |
| Price to Book Ratio | 16.73 |
| Enterprise Value to Revenue | 8.07 |
| Enterprise Value to EBIT | 43.7 |
| Enterprise Value to Net Income | 139 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 2.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 10.5000▲ 935.38% |
|---|---|
| Total Calls | 2,400▼ 99.97% |
| Total Puts | 25,200▼ 99.75% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.87%▼ 70.21% |
|---|---|
| Total Invested | $12.66B▼ 95.51% |
| Investors Holding | 1,487▼ 2690.00% |
ESG Score
No data
About Abbvie Inc
CEO: Richard Gonzalez Relevant Senate Committees
This committee provides the official revenue estimates and technical analysis for all tax legislation. Its reports directly influence corporate tax structures and capital investment credits, which are crucial for AbbVie's financial planning and profitability.
This powerful committee controls taxation, trade, and entitlement spending (like Medicare). Its decisions on corporate tax policy and Medicare drug pricing directly and profoundly impact AbbVie's profitability and market valuation.
This committee allocates discretionary federal spending, directly determining the precise cash flow for critical programs like scientific research (NIH) and healthcare initiatives (Medicare, Medicaid, VA), which are major revenue sources and regulatory environments for AbbVie.
This committee directly regulates the FDA and NIH, which are primary bodies overseeing drug approval, safety, and medical research funding – all critical aspects of AbbVie's business and stock performance.
This committee's oversight of antitrust laws directly impacts mega-mergers in the pharmaceutical industry, and its jurisdiction over intellectual property (patents) is absolutely critical for the valuation and business model of companies like AbbVie.